Particle accelerator

Radiation therapy takes advantage of cancer's poor DNA repair abilities – an oncologist and physicist explain how

Retrieved on: 
Wednesday, January 3, 2024

Ionizing radiation, or the emission of high-energy waves or particles, works as a therapy by damaging a cancer cell’s DNA.

Key Points: 
  • Ionizing radiation, or the emission of high-energy waves or particles, works as a therapy by damaging a cancer cell’s DNA.
  • It’s an effective tool for killing cancer cells because they are generally much less adept at DNA repair compared to healthy cells.
  • Damaging specific parts of DNA prevents cancer cells from reproducing, effectively killing them.

Fundamentals of radiation therapy

  • At the heart of radiation therapy lies the fundamental principle that cancer cells are more susceptible to radiation than healthy cells.
  • Sometimes resistance to radiation in cancer cells may be comparable or even greater than that of their neighboring cells.
  • When tumors lie close to vital organs that are highly sensitive to radiation, such as the brain or the bowels, it significantly limits the amount of radiation that can be delivered.

External beam radiation therapy

  • External beam radiation involves directing radiation from an outside source to a single part of the body.
  • Another form of radiotherapy is proton beam therapy, or PBT, which directs protons instead of X-rays at tumors.

Image-guided radiation therapy

  • By acting as the eyes of the care team, imaging reduced uncertainty about the location of tumors and improved the precision and accuracy of radiation therapy.
  • Newer linear accelerators are now incorporating MRIs, which significantly improve visualization of patient anatomy and tumors, further advancing treatment precision and accuracy.


Researchers are also adding positron emission tomography, or PET, scanners that provide information about the metabolic function of tumors. This advance makes it possible to increase the radiation dose specifically at the most active areas of tumors.

Adaptive therapy

  • An emerging approach to radiation therapy called adaptive therapy uses imaging to dynamically adjust treatment as the tumor or its positioning changes each day.
  • However, adaptive therapy may apply several adjustments or lead to a completely new treatment plan in order to address changes to the tumor’s condition over the course of treatment.
  • The fact that the process needs to be repeated multiple times renders adaptive therapy particularly resource-intensive and time-consuming.

Brachytherapy

  • Brachytherapy – stemming from the Greek word “brachys,” meaning “short” – is another widely used method in radiation therapy.
  • In contrast to external beam radiation therapy, where radiation often must pass through healthy tissue to reach cancer cells, brachytherapy applies radiation directly to the tumor.
  • The conventional approach to brachytherapy involved using needles to place or inject radioactive seeds inside or adjacent to the cancerous tissue.
  • An increasingly popular form of brachytherapy called high-dose rate brachytherapy involves using a tube to guide a more highly radioactive seed directly to the affected tissue before removing it after a few minutes.

Future of radiation therapy

  • Researchers are also exploring treatments using ions heavier than protons to more effectively damage DNA in cancer cells and enhance the efficacy of radiation therapy.
  • Advances in the field hint at a future of more personalized radiation therapy, highlighting the fusion of technology and medical expertise in the fight against cancer.


The authors do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

American Shared Hospital Services Enters Into Agreement to Acquire 60% Majority Interest in Three Radiation Therapy Cancer Centers in Rhode Island

Retrieved on: 
Monday, November 20, 2023

SAN FRANCISCO, CA, Nov. 20, 2023 (GLOBE NEWSWIRE) -- ​​via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (“ASHS” or the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems and services, today announced that it has entered into an Investment Purchase Agreement (the “IPA”) to purchase a 60% majority equity interest in the Southern New England Regional Cancer Center, LLC and Roger Williams Radiation Therapy, LLC, both Rhode Island limited liability companies (collectively, the “Target Companies”), as well as certain payor contracts, from GenesisCare USA, Inc., a Florida corporation (the “Seller”), for a purchase price of $2.85 million. ProspectCharterCARE, LLC d/b/a Roger Williams Medical Center and the Care New England (CNE) Health System each own 20% of the Target Companies.

Key Points: 
  • The Target Companies operate three fully functional turn-key radiation therapy cancer centers in Rhode Island, and all three sites are equipped with state-of-the-art cancer treatment technology using Linear Accelerators (LINACs) and comprehensive treatment planning software.
  • The centers are all located on or adjacent to hospital campuses and include the Southern New England Regional Cancer Centers d/b/a Maddock Radiation Therapy in Warwick, RI, and d/b/a Landmark Radiation Therapy in Woonsocket, RI.
  • The third facility is the Roger Williams Cancer Center d/b/a Roger Williams Radiation Therapy in Providence, RI.
  • These patients would have had to interrupt their life-saving treatment and attempt to seek radiation therapy elsewhere.

Global Radiation Therapy Market Forecast Report 2023-2027: A $13.28 Billion Market in 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 26, 2023

The "Global Radiation Therapy Market with Focus on LINAC: Insights & Forecast (2023-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Radiation Therapy Market with Focus on LINAC: Insights & Forecast (2023-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The global radiation therapy market is expected to reach US$13.28 billion in 2027, witnessing growth at a CAGR of 6.77%, over the period 2023-2027.
  • The global radiation therapy market can be categorized into external beam radiation therapy, internal beam radiation therapy and others (systemic radiotherapy) on the basis of type.
  • Depending upon the type, the global external beam radiation therapy market can be categorized into following categories: Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), Tomotherapy, Stereotactic Radiosurgery, Stereotactic Body Radiation Therapy and Proton Therapy.

Amcomri Entertainment to Provide Funding and International Distribution for Ground-Breaking Series “Paid in Full: The Battle for Payback”

Retrieved on: 
Wednesday, June 7, 2023

VANCOUVER, British Columbia, June 07, 2023 (GLOBE NEWSWIRE) -- Amcomri Entertainment Inc. (“Amcomri” or the “Company”) (NEO: AMEN) (OTC: AMNNF) (Frankfurt: 25YO), a global producer and distributor of independent movies, TV series and documentaries, today announced that its television and documentary subsidiary, Abacus Media Rights (“Abacus”), is providing funding and international distribution for the three-part docuseries, “Paid in Full: The Battle for Payback”. The project is a collaboration between Supercollider, Green Door Pictures and Pink Towel, and has been commissioned by CBC and the BBC. With the production connecting different eras in music history while highlighting racial inequality, the involvement of Amcomri Entertainment underscores a commitment to supporting impactful independent productions and addressing important issues within the industry.

Key Points: 
  • The project is a collaboration between Supercollider, Green Door Pictures and Pink Towel, and has been commissioned by CBC and the BBC.
  • “We are seeing ongoing strong demand for independent content, particularly on the TV side of our business,” said Robert Price, Chief Executive Officer of Amcomri.
  • “Our subsidiary, Abacus Media Rights, continues to represent and invest in a diverse repertoire of TV productions.
  • Abacus has also retained international sales distribution rights for the acclaimed series “Hope Street” and acquired global rights for the Emmy-nominated series “Legacy List with Matt Paxton”, expanding the global reach of Amcomri Entertainment’s extensive portfolio.

Medicaid Cancer Foundation Launches Health Fund in Response to Cancer Moonshot

Retrieved on: 
Monday, January 9, 2023

The Medical Director of Medicaid Cancer Foundation H.E Dr. Zainab Shinkafi Bagudu has expressed her dedication to supporting cancer treatment and care in Nigeria and beyond.

Key Points: 
  • Abuja, Nigeria--(Newsfile Corp. - January 9, 2023) - Medicaid Cancer Foundation announces the launch of the Medicaid Cancer Health Fund in the wake of President Joe Biden's reignition of the cancer moonshot in February 2022.
  • The Medicaid Cancer Health Fund will broaden access to cancer care services in Northern Nigeria by linking beneficiaries to discount/free cancer services through its existing network of partners and building a comprehensive cancer treatment centre in Abuja.
  • Medicaid Cancer Foundation is committed to leveraging local and global contacts to deliver a one-stop-shop for the full complement of cancer treatment services in Nigeria.
  • The roadmap announced at the White House Cancer Moonshot Summit in December 2022 opens the door for capital and human resource investment from the United States to accelerate access to quality cancer care services in Africa.

TTG Imaging Solutions Announces Acquisition of Acceletronics and RadParts

Retrieved on: 
Friday, October 7, 2022

PITTSBURGH, Oct. 7, 2022 /PRNewswire/ -- TTG Imaging Solutions, LLC (TTG) announced today the acquisition of Acceletronics, headquartered in Exton, PA, and sister company RadParts, headquartered in Haslett, MI. The acquisition closed on August 26, 2022.

Key Points: 
  • PITTSBURGH, Oct. 7, 2022 /PRNewswire/ -- TTG Imaging Solutions, LLC (TTG)announced today the acquisition of Acceletronics, headquartered in Exton, PA, and sister company RadParts, headquartered in Haslett, MI.
  • Matt Mastarone, President & CEO of TTG said, "The acquisition of both Acceletronics and RadParts cements TTG as a full-service provider to the radiation oncology industry.
  • We began this journey into LINAC in Q1 of 2022 with the acquisition of Vanguard Solutions and I welcome the team members from Acceletronics and RadParts into the TTG family."
  • Larry Day, CEO of Acceletronics and RadParts, added, "This merger/acquisition with TTG creates tremendous opportunity for the employees of Acceletronics and RadParts.

Global Radiotherapy Market Report 2022: Rising Cancer Prevalence Worldwide to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 17, 2022

Technological advancements in radiotherapy and the rising incidence of cancer are the major factors driving the growth of this market.

Key Points: 
  • Technological advancements in radiotherapy and the rising incidence of cancer are the major factors driving the growth of this market.
  • Additionally, growing awareness of the benefits of radiotherapy and the increasing use of particle therapy for cancer treatment are other factors driving the growth of this market.
  • The service segment, by type, is expected to register the highest growth rate in the global radiotherapy market during the forecast period 2022-2027.
  • Based on technology, the radiotherapy market has been segmented into external beam radiotherapy and internal beam radiotherapy.

Global Technetium Market (2021 to 2026) - Featuring American Elements, Bayer and Covidien Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, October 25, 2021

This report provides deep insights into the current and future state of the technetium market across various regions.

Key Points: 
  • This report provides deep insights into the current and future state of the technetium market across various regions.
  • The report examines the market drivers and restraints, along with the impact of Covid-19 on the market's growth, in detail.
  • According to the publisher, the global technetium market is expected to witness growth at a considerable rate during the forecast period.
  • Boasting high development, North America has been the largest market for global technetium due to the demand for advanced medical facilities here.

Chile Radiotherapy Market Size, Share & Trends Analysis 2021-2028 by Type (External Beam, Internal Beam, Systemic Radiotherapy), Application (Breast, Prostate, Lung, Colorectal, Head & Neck Cancer) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 1, 2021

The "Chile Radiotherapy Market Size, Share & Trends Analysis Report by Type (External Beam, Internal Beam, Systemic Radiotherapy), by Application (Breast, Prostate, Lung, Colorectal, Head & Neck Cancer), and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chile Radiotherapy Market Size, Share & Trends Analysis Report by Type (External Beam, Internal Beam, Systemic Radiotherapy), by Application (Breast, Prostate, Lung, Colorectal, Head & Neck Cancer), and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Chile radiotherapy market size is expected to reach USD 36.0 million by 2028.
  • The increasing prevalence of cancer and rising healthcare expenditure are factors expected to propel the growth over the forecast period.
  • There is a significant gap between the required and installed radiotherapy capacity in Chile.

Global IT consultancy firm Xebia Group acquires Appcino to accelerate digital transformation with powerful low-code competencies

Retrieved on: 
Wednesday, June 2, 2021

Appcino has delivered more than 600+ Enterprise apps across 100+ customers worldwide and has created multiple solution accelerators on these platforms to fast-track the overall transformation journey.

Key Points: 
  • Appcino has delivered more than 600+ Enterprise apps across 100+ customers worldwide and has created multiple solution accelerators on these platforms to fast-track the overall transformation journey.
  • Xebia is excited to add these capabilities to help our customers worldwide and help them speed up their digital transformation initiatives at scale."
  • Tarun Khatri, Devendra Natani and Akhilesh Natani, the Founders of Appcino said:"We are thrilled to be partnering with the Xebia team.
  • Joining forces with Appcino, a leader in low code consultancy & development, strengthens Xebia's position as a global digital leader and enhances its capability to augment its customers' technology landscape, further accelerating their business growth.